Skip to main content
JADPRO Live 2024 Main banner
Icon Legend
ICONS KEY
CE Credit Available
CE Credit Available
Pharmacology Credit Available
Pharmacology Credit Available
Poster Activities
Poster Activities
Surgical Oncology
Surgical Oncology

Full Schedule

  1. Home
  2. Full Schedule

Full Schedule

  • Thursday, November 14, 2024
  • 7:30 AM – 7:00 PM CT
    Registration
  • 9:00 AM – 11:00 AM CT
    Pre-Conference Workshop: Hands-On Procedure Training
    (Bone Marrow Aspiration, Lumbar Puncture, and Ommaya Reservoir Access)
  • 9:00 AM – 11:30 AM CT
    Pre-Conference Workshop: Clinical Trials: Increasing and Improving Design, Representation, and Access
  • 9:00 AM – 11:30 AM CT
    Pre-Conference Workshop: Imaging Modalities in Oncology Urgent Care
  • 9:00 AM – 11:30 AM CT
    Pre-Conference Workshop: Managing Thrombotic Challenges: Best Practices in Anticoagulation
  • 12:00 PM – 2:00 PM CT
    Pre-Conference Workshop: Hands-On Procedure Training
    (Bone Marrow Aspiration, Lumbar Puncture, and Ommaya Reservoir Access; repeat of 9:00 am workshop)
  • 12:00 PM – 2:30 PM CT
    Pre-Conference Workshop: A Case-Based Workshop for Better Symptom Management
  • 12:00 PM – 2:30 PM CT
    Pre-Conference Workshop: Help Is on the Way: Comprehensive Care of the Young Adult With Cancer
  • 12:00 PM – 2:30 PM CT
    Pre-Conference Workshop: Unraveling the Mysteries Behind Peripheral Blood Smears
  • 2:30 PM – 4:00 PM CT
    Independent CE-Accredited Satellite Symposium: The Principles of Care in Advanced NSCLC: An Advanced Practitioner’s Guide to Antibody-Drug Conjugates
  • 4:00 PM – 5:00 PM CT
    Non-CE Accredited Satellite Symposium: Uveal Melanoma and KIMMTRAK (Tebentafusp-tebn)
    Immunocore
  • 4:00 PM – 5:00 PM CT
    Non-CE-Accredited Satellite Symposium: Getting Started and Transitioning to Outpatient Care for Patients With Relapsed or Refractory Multiple Myeloma
    Pfizer Inc.
  • 4:00 PM – 5:00 PM CT
    Rare Disease Reception
  • 5:00 PM – 5:45 PM CT
    APSHO Annual Member Meeting
  • 6:00 PM – 8:00 PM CT
    Welcome Reception
  • Friday, November 15, 2024
  • 7:00 AM – 8:15 AM CT
    Breakfast Activity/Non-CE Accredited Satellite Symposium: A Treatment Option for Patients With Primary Advanced or Recurrent Endometrial Cancer
    GSK
  • 7:00 AM – 8:15 AM CT
    Breakfast Activity/Non-CE Accredited Satellite Symposium: CARVYKTI® Product Summary for Patient Care Teams
    Johnson & Johnson
  • 7:00 AM – 8:15 AM CT
    Breakfast Activity/Non-CE Accredited Satellite Symposium: Supporting Patients With HR+/HER2- mBC Throughout Their Treatment Journey
    Pfizer, Inc.
  • 7:00 AM – 8:15 AM CT
    Breakfast Activity/Non-CE Accredited Satellite Symposium: Treatment Option for Patients with Unresectable or Metastatic Melanoma​
    Bristol Myers Squibb
  • 7:00 AM – 8:15 AM CT
    Exhibit Hall Open & Continental Breakfast
  • 7:00 AM – 5:30 PM CT
    Registration
  • 8:20 AM – 8:30 AM CT
    Welcome & Opening Remarks
  • 8:30 AM – 9:45 AM CT
    Opening Panel Discussion: Understanding the Benefits and Pitfalls of Artificial Intelligence in Oncology
  • 9:45 AM – 4:30 PM CT
    Braindate
  • 9:50 AM – 10:50 AM CT
    Complicating “Factors”: When Malignancy and Non-Malignant Hematology Collide
  • 9:50 AM – 10:50 AM CT
    New Drug Updates in Solid Tumors
  • 10:50 AM – 11:20 AM CT
    APSHO Meet & Greet: Awards & Recognition Committee
  • 10:50 AM – 11:50 AM CT
    Exhibit Hall Open & Refreshment Break
  • 11:05 AM – 11:35 AM CT
    Exhibit Hall Presentation Theater: Clinical Considerations for the Treatment of mTNBC and HR+/HER2- mBC with an ADC
    Gilead
  • 11:05 AM – 11:35 AM CT
    Exhibit Hall Presentation Theater: Explore the current data that could help you recognize/assess candidates for a CDK4 & 6 inhibitor.
    Lilly
  • 11:05 AM – 11:50 AM CT
    Exhibit Hall Presentation Theater: Practical Management of AML with a BCL-2 Inhibitor
    AbbVie
  • 11:20 AM – 11:50 AM CT
    APSHO Meet & Greet: Communications Committee
  • 11:50 AM – 12:35 PM CT
    Cancer Complexities: Balancing Your Patient’s Comorbidities With Their Treatments
  • 11:50 AM – 12:35 PM CT
    Updates in HR-Positive HER2-Negative Metastatic Breast Cancer for the Advanced Practitioner
  • 12:25 PM – 2:00 PM CT
    Lunch Activity/Non-CE Accredited Satellite Symposium: The AEGEAN Regimen: Neoadjuvant IMFINZI® (durvalumab) + Platinum-Containing Chemotherapy Then Adjuvant IMFINZI for Resectable (Tumors ≥4 cm and/or Node Positive) NSCLC With No Known EGFR Mutations or ALK Rearrangements
    AstraZeneca
  • 12:25 PM – 2:00 PM CT
    Lunch Activity/Non-CE Accredited Satellite Symposium: Thrombotic Risk and Symptom Assessment in Patients With Polycythemia Vera | A Collaborative Approach to Identifying When to Intervene With Jakafi® (ruxolitinib)
    Incyte Corporation
  • 12:35 PM – 2:00 PM CT
    Exhibit Hall Open & Lunch
  • 12:35 PM – 2:00 PM CT
    Lunch Activity/Non-CE Accredited Satellite Symposium: A Consideration for Patients With Relapsed or Refractory Multiple Myeloma
    Johnson & Johnson
  • 12:35 PM – 2:00 PM CT
    Lunch Activity/Non-CE Accredited Satellite Symposium: Review of evidence-based data for an antibody-drug conjugate in combination with a PD-1 inhibitor for 1L la/mUC
    Astellas Pharma Inc. and Pfizer Oncology Inc.
  • 12:35 PM – 2:00 PM CT
    Lunch Activity/Non-CE Accredited Satellite Symposium: Subcutaneous Administration: An Alternative Route of Administration in Oncology Treatment​
    Bristol Myers Squibb
  • 1:15 PM – 1:45 PM CT
    APSHO Meet & Greet: Diversity Equity & Inclusion (DEI) Committee
  • 2:00 PM – 3:00 PM CT
    Keynote Address: The Resilience Blueprint: Navigating Change in the New Normal
  • 3:00 PM – 3:30 PM CT
    APSHO Meet & Greet: Board of Directors
  • 3:00 PM – 3:45 PM CT
    Moderated Posters: Clinical Posters, Industry Encore Posters, and APSHO Patient Advocacy Posters
  • 3:00 PM – 4:00 PM CT
    Exhibit Hall Open & Refreshment Break
  • 3:15 PM – 3:45 PM CT
    Exhibit Hall Presentation Theater: Breakthrough Innovation: The First and Only Bispecific T-cell Engager (BiTE®) Therapy for 2L+ Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
    Amgen
  • 3:15 PM – 3:45 PM CT
    Exhibit Hall Presentation Theater: Utilizing Gene Expression Profile (GEP) testing to Personalize Management for Patients with Cutaneous Malignancies
    Castle Biosciences
  • 3:15 PM – 3:45 PM CT
    ymphocytic Leukemia and Waldenström Macroglobulinemia Patient Populations
    Supported by Pharmacyclics, An Abbvie Company and Johnson & Johnson
  • 3:30 PM – 4:00 PM CT
    APSHO Meet & Greet: Membership Committee
  • 3:45 PM – 4:15 PM CT
    Updates in the Surgical Management of Small Renal Tumors
  • 3:45 PM – 4:45 PM CT
    Successful Management of Patients Receiving Bispecific Antibodies for Hematologic Malignancies
  • 3:45 PM – 5:00 PM CT
    Oral Poster Presentations (Part 1)
  • 4:15 PM – 4:45 PM CT
    Updates in the Surgical Management of Small Lung Tumors
  • 5:00 PM – 5:45 PM CT
    Independent CE-Accredited Satellite Symposium: Treatment Advances For Advanced Prostate Cancer: Guideline Updates and Newer Therapies
  • 5:45 PM – 6:30 PM CT
    Independent CE-Accredited Satellite Symposium: Opportunities for Improved Outcomes: The Role of Targeted Therapies in Metastatic Urothelial Carcinoma
  • 6:30 PM – 8:30 PM CT
    Independent CE-Accredited Dinner Satellite Symposium: Optimizing the Patient Journey in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Evolving Guidelines, Emerging Options, and Multidisciplinary Management Strategies
  • Saturday, November 16, 2024
  • 7:00 AM – 8:15 AM CT
    Breakfast Activity/Non-CE Accredited Satellite Symposium: A Treatment Option for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma
    Merck
    Seating is available on a first-come, first-served basis.
  • 7:00 AM – 8:15 AM CT
    Breakfast Activity/Non-CE Accredited Satellite Symposium: An Outpatient Treatment Option for Patients with 3L+ Follicular Lymphoma, A Fixed-Duration Treatment Option for 3L+ Diffuse Large B-Cell Lymphoma
    Genentech
    Seating is available on a first-come, first-served basis.
  • 7:00 AM – 8:15 AM CT
    Breakfast Activity/Non-CE Accredited Satellite Symposium: Treatment Options for Patients with Metastatic Non-Small Cell Lung Cancer​
    Bristol Myers Squibb
    Seating is available on a first-come, first-served basis.
  • 7:00 AM – 8:15 AM CT
    Breakfast Activity/Non-CE Accredited Satellite Symposium: Understanding AYVAKIT for Indolent Systemic Mastocytosis (ISM)
    Blueprint Medicines
    Seating is available on a first-come, first-served basis.
  • 7:00 AM – 8:15 AM CT
    Exhibit Hall Open & Continental Breakfast
  • 7:00 AM – 5:30 PM CT
    Registration
  • 8:20 AM – 8:30 AM CT
    Opening Remarks & APSHO FAPO Recognition Presentation
  • 8:30 AM – 8:40 AM CT
    The Annual Mary Pazdur Award Presentation
  • 8:45 AM – 9:15 AM CT
    The Mary Pazdur Award Recipient Lecture
  • 9:20 AM – 10:20 AM CT
    Diagnostic Imaging in Surgical Oncology
  • 9:20 AM – 10:20 AM CT
    Harnessing the Power of Predictive Biomarkers in Precision Oncology
  • 9:20 AM – 10:20 AM CT
    Managing Dermatologic Side Effects in Patients With Cancer
  • 9:45 AM – 4:30 PM CT
    Braindate
  • 10:25 AM – 10:55 AM CT
    APSHO Meet & Greet: Radiation Oncology Committee
  • 10:25 AM – 11:25 AM CT
    Exhibit Hall Open & Refreshment Break
  • 10:25 AM – 11:25 AM CT
    Moderated Posters: Clinical Posters, Industry Encore Posters, and APSHO Patient Advocacy Posters
  • 10:35 AM – 11:05 AM CT
    Exhibit Hall Presentation Theater: HER2 Expression Informs Clinical Decision Making in HER2-Low mBC
    Daiichi Sankyo, Inc. and AstraZeneca
  • 10:35 AM – 11:05 AM CT
    Exhibit Hall Presentation Theater: Understanding the role of pharmacists in the management of Low-risk Myelodysplastic Syndromes (MDS)
    Bristol Myers Squibb
  • 10:35 AM – 11:20 AM CT
    Exhibit Hall Presentation Theater: Diving Deep into Venetoclax Fixed Treatment Duration Regimens and Time Off Treatment
    AbbVie
  • 10:55 AM – 11:25 AM CT
    APSHO Meet & Greet: Research Quality & Improvement (RQI) Committee
  • 11:30 AM – 12:30 PM CT
    Addressing Cancer Survivorship in Vulnerable Populations
  • 11:30 AM – 12:30 PM CT
    Advancing Care for Patients with Resectable NSCLC
  • 11:30 AM – 12:30 PM CT
    Fast Tracking Recovery: Enhancing Surgical Outcomes in Oncology
  • 12:30 PM – 1:45 PM CT
    Exhibit Hall Open & Lunch
  • 12:30 PM – 1:45 PM CT
    Lunch Activity/Non-CE Accredited Satellite Symposium: A First-Line Treatment Option for Adults with Symptomatic Anemia Due To Lower-Risk MDS
    Bristol Myers Squibb
    Seating is available on a first-come, first-served basis.
  • 12:30 PM – 1:45 PM CT
    Lunch Activity/Non-CE Accredited Satellite Symposium: The Facts on the Combined Power of RYBREVANT® + LAZCLUZE for the First-Line Treatment of EGFR+ Locally Advanced or mNSCLC
    Johnson & Johnson
    Seating is available on a first-come, first-served basis.
  • 12:30 PM – 1:45 PM CT
    Lunch Activity/Non-CE Accredited Satellite Symposium: Treatment of Adults With Certain BRAF–Mutated Metastatic Melanoma, Colorectal, and Non-Small Cell Lung Cancers
    Pfizer, Inc.
    Seating is available on a first-come, first-served basis.
  • 12:30 PM – 2:00 PM CT
    Lunch Activity/Non-CE Accredited Satellite Symposium: A Coordinated Care Team Approach to the Management of Patients Taking Jakafi for Chronic Graft-Versus-Host Disease
    Incyte Corporation
    Seating is available on a first-come, first-served basis.
  • 1:15 PM – 1:45 PM CT
    APSHO Meet & Greet: Education Committee
  • 1:45 PM – 2:15 PM CT
    Providing Culturally Inclusive Care in the Surgical Oncology Setting
  • 1:45 PM – 2:45 PM CT
    Fundamentals of Radiation Oncology: What the Advanced Practitioner Needs to Know
  • 1:45 PM – 2:45 PM CT
    New Drug Updates: Investigational Therapeutics in the Pipeline
  • 2:15 PM – 2:45 PM CT
    Principles of Wound Care in the Surgical Oncology Setting
  • 2:45 PM – 4:00 PM CT
    Exhibit Hall Open & Refreshment Break
  • 3:00 PM – 3:30 PM CT
    APSHO Meet & Greet: Professional Development & Leadership (PD&L) Committee
  • 3:00 PM – 3:30 PM CT
    Exhibit Hall Presentation Theater: Rethink Thalassemia: A Deep Dive Into Its Pathophysiology, Risks, and Complications.
    Agios Pharmaceuticals
  • 3:00 PM – 3:45 PM CT
    Exhibit Hall Presentation Theater: A STEP FORWARD - Initiating VENCLEXTA Treatment in Patients with CLL
    AbbVie
  • 3:00 PM – 3:45 PM CT
    Exhibit Hall Presentation Theater: Redefining Frontline Therapy in Patients with Newly Diagnosed Multiple Myeloma: A Focus on the Outcomes of Transplant-Eligible and Transplant-Ineligible Patients as seen in the PERSEUS and MAIA Trials
    Johnson & Johnson
  • 3:45 PM – 5:00 PM CT
    New-to-Oncology Roundtables
  • 4:00 PM – 5:00 PM CT
    Evidence-Based Strategies for Well-Being and Professional Fulfillment
  • 4:00 PM – 5:00 PM CT
    Optimizing the Care of Patients With Higher-Risk Myelofibrosis
  • 5:00 PM – 6:30 PM CT
    Independent CE-Accredited Satellite Symposium: Novel Therapeutics and Essential Strategies for Optimized Outcomes in Relapsed/Refractory Multiple Myeloma
  • 5:45 PM – 6:30 PM CT
    Independent CE-Accredited Satellite Symposium: Updates and Evidence-Based Strategies in Non-Small Cell Lung Cancer: A Focus on Molecular Testing, Targeted Treatment, and Adverse Event Management
  • 6:30 PM – 8:30 PM CT
    Independent CE-Accredited Satellite Dinner Symposium: The Amazing Case: Charting the Course of Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Relapsed/Refractory Follicular Lymphoma with Bispecific Antibodies
  • Sunday, November 17, 2024
  • 6:30 AM – 12:00 PM CT
    Registration
  • 7:30 AM – 8:30 AM CT
    Oral Poster Presentations (Part 2)
  • 8:30 AM – 9:30 AM CT
    Breakfast Activity/Non-CE Accredited Satellite Symposium
    Astellas
  • 8:30 AM – 9:30 AM CT
    Breakfast Activity/Non-CE Accredited Satellite Symposium: A Nurse's Guide to EGFR TKI Adverse Reaction Management
    AstraZeneca
  • 8:30 AM – 9:30 AM CT
    Breakfast Activity/Non-CE Accredited Satellite Symposium: CAR T Cell Therapy for 2L Large B-Cell Lymphoma (LBCL) and 3L Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
    Bristol Myers Squibb
  • 8:30 AM – 9:30 AM CT
    Continental Breakfast
  • 9:30 AM – 10:30 AM CT
    New Drug Updates: Hematologic Malignancies
  • 9:30 AM – 10:30 AM CT
    Safe Prescribing in the Cancer Patient With Substance Use Disorder
  • 10:35 AM – 11:20 AM CT
    Beyond Platinum: Current Approaches to Advanced Bladder Cancer
  • 10:35 AM – 11:20 AM CT
    More Than Pain: New Therapies and Considerations for Sickle Cell Disease
  • 11:30 AM – 12:30 PM CT
    Improving Patient Care Through Administrative Time for the Advanced Practitioner
  • 12:30 PM CT
    Conference Concludes
  • Wednesday, November 20, 2024
  • 7:30 AM – 8:30 AM CT
    Oral Poster Presentations (Part 2)
  • 8:30 AM – 9:45 AM CT
    Opening Panel Discussion: Understanding the Benefits and Pitfalls of Artificial Intelligence in Oncology
  • 8:45 AM – 9:15 AM CT
    The Mary Pazdur Award Recipient Lecture
  • 9:20 AM – 10:20 AM CT
    Diagnostic Imaging in Surgical Oncology
  • 9:20 AM – 10:20 AM CT
    Harnessing the Power of Predictive Biomarkers in Precision Oncology
  • 9:20 AM – 10:20 AM CT
    Managing Dermatologic Side Effects in Patients With Cancer
  • 9:30 AM – 10:30 AM CT
    New Drug Updates: Hematologic Malignancies
  • 9:30 AM – 10:30 AM CT
    Safe Prescribing in the Cancer Patient With Substance Use Disorder
  • 9:50 AM – 10:50 AM CT
    Complicating “Factors”: When Malignancy and Non-Malignant Hematology Collide
  • 9:50 AM – 10:50 AM CT
    New Drug Updates in Solid Tumors
  • 10:35 AM – 11:20 AM CT
    Beyond Platinum: Current Approaches to Advanced Bladder Cancer
  • 10:35 AM – 11:20 AM CT
    More Than Pain: New Therapies and Considerations for Sickle Cell Disease
  • 11:30 AM – 12:30 PM CT
    Addressing Cancer Survivorship in Vulnerable Populations
  • 11:30 AM – 12:30 PM CT
    Advancing Care for Patients with Resectable NSCLC
  • 11:30 AM – 12:30 PM CT
    Fast Tracking Recovery: Enhancing Surgical Outcomes in Oncology
  • 11:30 AM – 12:30 PM CT
    Improving Patient Care Through Administrative Time for the Advanced Practitioner
  • 11:50 AM – 12:35 PM CT
    Cancer Complexities: Balancing Your Patient’s Comorbidities With Their Treatments
  • 11:50 AM – 12:35 PM CT
    Updates in HR-Positive HER2-Negative Metastatic Breast Cancer for the Advanced Practitioner
  • 1:45 PM – 2:15 PM CT
    Providing Culturally Inclusive Care in the Surgical Oncology Setting
  • 1:45 PM – 2:45 PM CT
    Fundamentals of Radiation Oncology: What the Advanced Practitioner Needs to Know
  • 1:45 PM – 2:45 PM CT
    New Drug Updates: Investigational Therapeutics in the Pipeline
  • 2:00 PM – 3:00 PM CT
    Keynote Address: The Resilience Blueprint: Navigating Change in the New Normal
  • 2:15 PM – 2:45 PM CT
    Principles of Wound Care in the Surgical Oncology Setting
  • 3:45 PM – 4:15 PM CT
    Updates in the Surgical Management of Small Renal Tumors
  • 3:45 PM – 4:45 PM CT
    Successful Management of Patients Receiving Bispecific Antibodies for Hematologic Malignancies
  • 3:45 PM – 5:00 PM CT
    Oral Poster Presentations (Part 1)
  • 4:00 PM – 5:00 PM CT
    Evidence-Based Strategies for Well-Being and Professional Fulfillment
  • 4:00 PM – 5:00 PM CT
    Optimizing the Care of Patients With Higher-Risk Myelofibrosis
  • 4:15 PM – 4:45 PM CT
    Updates in the Surgical Management of Small Lung Tumors